1. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report
- Author
-
Hong Xu, Zhihui Hong, Meiling Xu, Yuehong Kong, Yifu Ma, Chanchan Shan, Pengfei Xing, and Liyuan Zhang
- Subjects
immunotherapy ,radiotherapy ,GM-CSF ,gastric cancer ,pMMR ,case report ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Patients with metastatic gastric cancer had limited treatments and often had a somber prognosis, especially when patients were unable to tolerate high-intensity cytotoxic treatment due to poor physical condition or organ dysfunction after the failure of standard therapy. Here, we reported a metastatic and proficient mismatch repair (pMMR) gastric adenocarcinoma patient with the Eastern Cooperative Oncology Group (ECOG) performance status score of 2 associated with hypoproteinemia and fatigue, and poor appetite that was unable to tolerate high-intensity therapy after several chemotherapy regimens and anti-angiogenic therapy. After receiving novel triple-combination therapy, which consists of PD-1 inhibitor, Radiotherapy and Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy (PRaG for short), the patient achieved a complete response (CR) with a progression-free survival time of 14 months, and ECOG performance status score improved from 2 to 0. A significant systemic effect was observed in this case and the PRaG triple-combination therapy might provide a novel treatment strategy for metastatic pMMR gastric cancer patients.
- Published
- 2022
- Full Text
- View/download PDF